Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propionyl-L-carnitine (ST261) for mild ulcerative colitis in patients on stable oral therapy
2011-004765-32Phase 3Terminated
- Sponsor
- Leadiant Biosciences
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing ST261 modified-release with Placebo (2 arms). Primary endpoint: Clinical and endoscopic remission at end of treatment. Started Dec 2011; status: terminated.
02
Drugs
propionyl-L-carnitine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2011-004765-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004765-32.